Natixis Travere Therapeutics, Inc. Transaction History

Natixis

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $217,740 - $491,625	28,500 Added 21.11%	163,500 $1.46 Million
Q2 2023 Aug 11, 2023	BUY	$15.3 - $22.61 $1.45 Million - $2.14 Million	94,700 Added 234.99%	135,000 $2.07 Million
Q1 2023 May 12, 2023	SELL	$17.82 - $22.89 $15,574 - $20,005	-874 Reduced 2.12%	40,300 $906,000
Q4 2022 Feb 24, 2023	SELL	$18.47 - $26.14 $1.09 Million - $1.54 Million	-58,826 Reduced 58.83%	41,174 $865,000
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $2.29 Million - $2.86 Million	100,000 New	100,000 $2.56 Million
Q2 2022 Aug 12, 2022	SELL	$20.94 - $30.01 $1.37 Million - $1.96 Million	-65,392 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$23.61 - $30.6 $1.54 Million - $2 Million	65,392 New	65,392 $1.69 Million

196

84.9M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.